Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-03597812 in relapsed/refractory acute myeloid leukemia
NCT06549790Phase 1Recruiting
- Sponsor
- Nerviano Medical Sciences
- Start
- Oct 2024
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NMS-03597812 in acute myeloid leukemia (AML) (4 arms), sponsored by Nerviano Medical Sciences. Primary endpoints: Adverse Events at 13 months and Complete Remission at 12 months. Started Oct 2024; status: recruiting.
02
Drugs
NMS-03597812
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06549790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549790.